Member Info for gadgie

Crack on then you Bell End

Straight from the Horses mouth .... as stated today !

Yeah I do hope they talk about possible dual listing Aim and Nas ..... Best way forward IMHO without letting go

Terry the Twat .... Wyn the Bore

Bloody Hell on a Wed"s as well :)

Really upped their game with Comms .... Thankyou !

Excellent Post !!

Only way forward without letting go of World Beating Treatments .... Dual Listing no need to license out keep it all in house ....How many times has AS hinted this year ?

Hi ok many thanks .... that should have raised a few eyebrows .... TOP researcher GMCC !!

Excellent Find GMCC ... Are we formally presenting that prior to AGM , can't see any Bio conferences ?

Wyn and Terry in Scratby selling Ice Creams

We are going to assist with green energy millions of Solar Panels ....Getting Unreal

Http://affyxell.com/bbs/?so_table=news_en&mode=VIEW&num=18&category=&findType=&findWord=&sort1=&sort2=&page=1

AffyXell Therapeutics Co., Ltd. presented the results of the Efficacy PoC evaluation of AFX001, a genetically engineered MSC under development for acute graft-versus-host disease (aGVHD), at the International Society for Cell Therapy (ISCT 2023) held in Paris, France.

AFX001 is an MSC therapeutic designed to secreted Affimer® molecules targeting CD40L based on AffyXell’s platform technology.

AffyXell confirmed the clinical score improvement through the xenograft GVHD model, and explained that the treatment effect of GVHD can be expected by suppressing the activity of T cells and B cells.

Currently, AffyXell Therapeutics Co., Ltd. is conducting non-clinical trials for IND submission of AFX001 for aGVHD.

Just topped up very tight between sales and buy's

Loving the Comm's Al will we get another on Tue's ?

Https://medicalxpress.com/news/2023-05-rapid-diagnostic-multiple-resistance-important.html

https://kabla-mx.translate.goog/pruebasrapidas/resist5-oknvi-carbapenemasas-coris/?_x_tr_sl=es&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc

https://bestbion.com/wp-content/uploads/2022/01/bestbiondx-carbapenemasen-resist-bc-rescape.pdf

The U.K. IVD market reached $4.6 billion in 2022, according to an estimate by Kalorama Information, a sister brand of LabPulse, in its 30-Country IVD Market Atlas.

The U.K. market is expected to grow just under 3% per year for the next five years, the report said, faster than Italy, France, or the Netherlands, and at about the same rate as Germany.

https://www.labpulse.com/business-insights/article/15446997/uk-ivd-market-grows-to-46-billion-brexit-not-a-factor

We have just tapped into a multi billion pound IVD Market and Launch D are about to go into Germany one of the biggest markets in Europe

https://www.globenewswire.com/en/news-release/2022/12/19/2576026/0/en/In-Vitro-Diagnostics-IVD-Market-Size-Share-to-Surpass-141-16-Billion-by-2028-Vantage-Market-Research.html

Very pleased you are on board and very pleased with your input thank you ..... now crack on !

Sensitivity & Specificity excellent Results .....

https://www.corisbio.com/pdf/Products/Coris-RESIST-D-CUS-10-RR-02-2023-03-V1.pdf